Compare Stocks

→ [Urgent!] Generational Wealth Gameplan (From Crypto 101 Media) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ENDV Endonovo Therapeutics	$0.00	$0.00	$0.00 ▼ $0.02	$1.07M	-1.41	3.07 million shs	349,914 shs
GNPX Genprex	$2.21 -3.9%	$3.77	$2.20 ▼ $46.00	$4.39M	-0.61	46,865 shs	20,532 shs
NEVPF Abliva AB (publ)	$0.01	$0.01	$0.01 ▼ $0.02	N/A	N/A	N/A	N/A
RELV Reliv' International	$3.80	$3.51	$2.50 ▼ $4.42	$6.64M	-0.1	23,200 shs	N/A
REXN Rexahn Pharmaceuticals		$2.06	$1.26 ▼ $4.26	$8.11M	0.98	162,968 shs	2,579 shs

7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ENDV Endonovo Therapeutics	-25.00%	-7.69%	+4.35%	-74.74%	-83.45%
GNPX Genprex	-4.33%	-23.53%	-45.97%	-73.26%	-94.18%
NEVPF Abliva AB (publ)	0.00%	0.00%	0.00%	-50.00%	0.00%
RELV Reliv' International	+4.40%	+4.40%	+2.98%	+2.70%	-3.06%
REXN Rexahn Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%

Could Bitcoin Literally FORCE This Crypto To Rocket Up? (Ad)

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

>>Click here to find out what it is.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ENDV Endonovo Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
GNPX Genprex	4.5881 of 5 stars	3.5	5.0	0.0	4.7	3.3	0.8	1.3
NEVPF Abliva AB (publ)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
RELV Reliv' International	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
REXN Rexahn Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ENDV Endonovo Therapeutics	N/A	N/A	N/A	N/A
GNPX Genprex	3.00	Buy	$10.00	352.49% Upside
NEVPF Abliva AB (publ)	N/A	N/A	N/A	N/A
RELV Reliv' International	N/A	N/A	N/A	N/A
REXN Rexahn Pharmaceuticals	N/A	N/A	N/A	N/A

Current Analyst Ratings

Latest GNPX, ENDV, RELV, REXN, and NEVPF Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
4/3/2024	GNPX Genprex	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
3/25/2024	GNPX Genprex	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy	$10.00

(Data available from 4/18/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ENDV Endonovo Therapeutics	$140K	5.71	N/A	N/A	($0.15) per share	-0.02
GNPX Genprex	N/A	N/A	N/A	N/A	$4.99 per share	N/A
NEVPF Abliva AB (publ)	N/A	N/A	N/A	N/A	$0.04 per share	N/A
RELV Reliv' International	$35.06M	0.19	$0.09 per share	44.53	$6.36 per share	0.60
REXN Rexahn Pharmaceuticals	N/A	N/A	N/A	N/A	$2.48 per share	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ENDV Endonovo Therapeutics	-$18.48M	N/A	0.00	∞	N/A	-1,717.21%	N/A	-408.63%	N/A
GNPX Genprex	-$30.86M	-$24.80	N/A	N/A	N/A	N/A	-245.62%	-185.50%	5/27/2024 (Estimated)
NEVPF Abliva AB (publ)	-$8.45M	N/A	0.00	∞	N/A	N/A	-63.75%	-57.93%	N/A
RELV Reliv' International	-$440K	N/A	N/A	∞	N/A	-0.61%	-1.89%	-1.31%	N/A
REXN Rexahn Pharmaceuticals	-$8.64M	N/A	0.00	N/A	N/A	N/A	-72.60%	-55.68%	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ENDV Endonovo Therapeutics	N/A	N/A	N/A	N/A	N/A
GNPX Genprex	N/A	N/A	N/A	N/A	N/A
NEVPF Abliva AB (publ)	N/A	N/A	N/A	N/A	N/A
RELV Reliv' International	N/A	N/A	N/A	N/A	N/A
REXN Rexahn Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ENDV Endonovo Therapeutics	N/A	N/A	N/A
GNPX Genprex	N/A	2.31	2.31
NEVPF Abliva AB (publ)	N/A	6.60	6.60
RELV Reliv' International	0.05	1.70	1.04
REXN Rexahn Pharmaceuticals	N/A	3.37	3.37

Ownership

Institutional Ownership

Company	Institutional Ownership
ENDV Endonovo Therapeutics	N/A
GNPX Genprex	14.05%
NEVPF Abliva AB (publ)	N/A
RELV Reliv' International	7.95%
REXN Rexahn Pharmaceuticals	7.49%

Insider Ownership

Company	Insider Ownership
ENDV Endonovo Therapeutics	5.61%
GNPX Genprex	11.54%
NEVPF Abliva AB (publ)	N/A
RELV Reliv' International	31.18%
REXN Rexahn Pharmaceuticals	1.10%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
ENDV Endonovo Therapeutics	1	333.04 million	314.36 million	Not Optionable
GNPX Genprex	31	1.91 million	1.69 million	Optionable
NEVPF Abliva AB (publ)	8	N/A	N/A	Not Optionable
RELV Reliv' International	91	1.75 million	N/A	Not Optionable
REXN Rexahn Pharmaceuticals	5	4.48 million	N/A	Optionable

GNPX, ENDV, RELV, REXN, and NEVPF Headlines

Source	Headline
	Aurinia Pharmaceuticals Inc AUPH morningstar.com - February 16 at 5:49 PM
	MaxCyte Appoints Douglas Swirsky as Chief Financial Officer benzinga.com - March 27 at 6:16 PM
	Rexahn: Holes Galore in Serdaxin Data thestreet.com - January 1 at 6:09 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Endonovo Therapeutics

OTCMKTS:ENDV

Endonovo Therapeutics, Inc., a biotechnology company, develops, manufactures, and distributes non-invasive Electroceutical medical devices for regenerative medicine. The company offers SofPulse, a non-invasive Electroceutical therapeutic device for the palliative treatment of soft tissue injuries, chronic wounds, and post-operative pain and edema. Its Electroceuticals medical device is also used for the treatment of cardiovascular diseases, chronic kidney, liver diseases, non-alcoholic steatohepatitis, cardiovascular and peripheral artery diseases, and ischemic stroke, as well as for central nervous system disorders, such as traumatic brain injury, acute concussions, post-concussion syndrome, stroke, and multiple sclerosis. Endonovo Therapeutics, Inc. was founded in 2008 and is based in Woodland Hills, California.

Genprex

NASDAQ:GNPX

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) that is in Phase 1/2 and 2 clinical trials to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002 for the treatment of type 1 diabetes, and GPX-003 for the treatment of type 2 diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.

Abliva AB (publ)

OTCMKTS:NEVPF

Abliva AB (publ), a clinical-stage biotech company, develops medicines for the treatment of primary mitochondrial diseases. The company is developing KL1333 that is in Phase 2/3 clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT that is in Phase 1b/2a clinical study for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.

Reliv' International

NASDAQ:RELV

Reliv' International, Inc. develops and markets nutritional supplements that address basic nutrition, specific wellness needs, weight management, and sports nutrition. The company's basic nutritional supplements are formulated to provide a balanced and complete level of supplementation for the consumer. Its principal products include Reliv Classic, Reliv Now, Innergize!, and FibRestore along with LunaRich X capsules. The company markets and sells its products through a direct selling system of independent distributors in the United States, Australia, Austria, Canada, France, Germany, Indonesia, Ireland, Malaysia, Mexico, the Netherlands, New Zealand, the Philippines, and the United Kingdom. Reliv' International, Inc. was founded in 1988 and is headquartered in Chesterfield, Missouri.

Rexahn Pharmaceuticals

NASDAQ:REXN

Ocuphire Pharma, Inc. engages in the research and development of ophthalmic biopharmaceutical products. It focuses on developing and commercializing therapies for the treatment of several eye disorders. The company was founded by Mina Patel Soouch and Alan R. Meyer in February 2018 and is headquartered in Farmington Hills, MI.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial